Coherus Oncology CHRS
NASDAQ CHRS
$0.75 +0.00 (+0.56%)
As of: Nov 6, 2026 · 9:54 AM EST

Coherus Oncology (CHRS) Construction in Progress (2015)

Updated

Coherus Oncology's Construction in Progress was $2.2 million in Q3 2015.

Analysis

Coherus Oncology (CHRS) Construction in Progress (2015) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Construction in Progress (Qtr)
1 Eli Lilly 1,221.54 Bn 1,195.15 Bn 20.46 Bn -
2 Johnson & Johnson 650.21 Bn 570.07 Bn 17.30 Bn -
3 AbbVie 508.24 Bn 476.24 Bn 13.12 Bn -
4 Merck 360.07 Bn 323.01 Bn 13.19 Bn -
5 Novartis Ag 312.26 Bn 285.49 Bn - -
6 Astrazeneca 285.31 Bn 259.20 Bn 13.26 Bn -
7 Amgen 247.74 Bn 199.39 Bn 7.58 Bn -
8 Gilead Sciences 207.12 Bn 182.22 Bn 6.73 Bn -
9 Pfizer 166.13 Bn 113.48 Bn 12.56 Bn -
10 Coherus Oncology 116.17 Mn -519.97 Mn 10.07 Mn -
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2015 2.20 Mn
API Access

Coherus Oncology Construction in Progress API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=construction-in-progress&ticker=CHRS&period=max&api_key=YOUR_API_KEY